Skip to main content
. Author manuscript; available in PMC: 2013 Oct 28.
Published in final edited form as: Curr Cancer Drug Targets. 2010 May;10(3):319–331. doi: 10.2174/156800910791190229

Fig. (6). MI-319 orally inhibits tumor growth in Capan-2 (wt-p53) and not in BxPC-3 (mut-p53) xenograft animal model.

Fig. (6)

(A) Capan-2 xenografts were inoculated subcutaneously in SCID mice. Once transplanted, fragments developed into palpable tumors (about 60 mg), groups of 7 animals were removed randomly and assigned to two treatment groups. Mice were administered MI-319 orally at 300 mg/kg for fourteen consecutive days. (○) Vehicle Control and (▲) MI-319 treated group. (B) MI-319 did not cause any loss in mice body weight during the course of treatment. (○) Vehicle Control and (■) MI-319 treated group. (C) BxPC-3 xenografts were established and treated with MI-319 similar to Capan-2 in SCID mice. (○) Vehicle Control and (■) MI-319 treated group. (D) MI-319 did not cause any loss in mice body weight during the course of treatment. (○) Vehicle Control and (■) MI-319 treated group.